Inventory

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventory

Inventory

Inventory consists of the following:

(in thousands)	DECEMBER 31, 2018
Raw materials	$	836
Work-in-process	6,885
Finished goods	2,391
Total inventory	$	10,112

The Company commenced capitalizing inventory for Rhopressa^® upon FDA approval of Rhopressa^® on December 18, 2017. No inventory was produced from the FDA approval date through the end of 2017; therefore, no inventory was capitalized on the consolidated balance sheet as of December 31, 2017.